Table Of Contents

1. Introduction

 1.1 Market Definition & Scope

 1.2 Research Assumptions & Abbreviations

 1.3 Research Methodology

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size By Treatment Type

  2.3.2 Market Size By Drug / Therapy Class

  2.3.3 Market Size By Route of Administration

  2.3.4 Market Size By End User

 2.4 Market Share & Bps Analysis By Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

 3.4 Industry Supply Chain Analysis

  3.4.1 Raw Material Suppliers

  3.4.2 Manufacturers

  3.4.3 Distributors/Suppliers

  3.4.4 Customers/End-Users

 3.5 Industry Life Cycle Assessment

 3.6 Parent Market Overview

 3.7 Market Risk Assessment

4. Statistical Insights & Trends Reporting

 4.1 Treatment Utilization Analysis & Forecast

  4.1.1 Overview

  4.1.2 Treatment Utilization Analysis By Treatment Type, 2022–2035

         4.1.3 Treatment Utilization Analysis By Drug / Therapy Class, 2022–2035

        4.1.4 Treatment Utilization Analysis By Route of Administration, 2022–2035

        4.1.5 Treatment Utilization Analysis By End User, 2022–2035

 4.2 Depression Prevalence & Patient Pool Analysis

  4.2.1 Global Depression Burden Assessment

  4.2.2 Treatment-Resistant Depression Patient Population Analysis

  4.2.3 Diagnosis & Treatment Rate Assessment

 4.3 Healthcare Infrastructure & Access Analysis

  4.3.1 Psychiatric Care Capacity Assessment

  4.3.2 Specialized Treatment Center Analysis

  4.3.3 Mental Health Accessibility Trends

5. Treatment-Resistant Depression (TRD) Treatment Market Segmental Analysis & Forecast, By Treatment Type, 2022–2035, Value (USD Billion)

5.1 Introduction

 5.2 Pharmacological Therapies

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022–2035

 5.3 Ketamine & Esketamine Therapies

     5.4 Neuromodulation Therapies (TMS, DBS, VNS)

     5.5 Psychedelic-Assisted Therapies

     5.6 Digital & Combination Therapies

6. Treatment-Resistant Depression (TRD) Treatment Market Segmental Analysis & Forecast, By Drug / Therapy Class, 2022–2035, Value (USD Billion)

    6.1 Introduction

 6.2 SSRIs & SNRIs Augmentation

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022–2035

 6.3 Atypical Antipsychotic Augmentation

    6.4 NMDA Receptor Modulators

    6.5 Neuromodulation Therapies

    6.6 Emerging Novel Therapies

7. Treatment-Resistant Depression (TRD) Treatment Market Segmental Analysis & Forecast, By Route of Administration, 2022–2035, Value (USD Billion)

    7.1 Introduction

 7.2 Oral

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022–2035

 7.3 Intranasal

 7.4 Intravenous

 7.5 Device-Based Treatment        

 7.6 Others

8. Treatment-Resistant Depression (TRD) Treatment Market Segmental Analysis & Forecast, By End User, 2022–2035, Value (USD Billion)

    8.1 Introduction

 8.2 Hospitals

  8.2.1 Key Trends

  8.2.2 Market Size & Forecast, 2022–2035

 8.3 Psychiatric Clinics

    8.4 Specialty Mental Health Centers

    8.5 Academic & Research Institutes

    8.6 Home-Based & Digital Care Providers

    8.7 Others

9. Treatment-Resistant Depression (TRD) Treatment Market Segmental Analysis & Forecast By Region, 2022–2035, Value (USD Billion)

9.1 Introduction

9.2 North America

 9.2.1 Key Trends

 9.2.2 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Treatment Type, 2022–2035

 9.2.3 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Drug / Therapy Class, 2022–2035

 9.2.4 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Route of Administration, 2022–2035

 9.2.5 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By End User, 2022–2035

 9.2.6 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Country, 2022–2035

  9.2.6.1 USA

  9.2.6.2 Canada

9.3 Europe

 9.3.1 Key Trends

 9.3.2 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Treatment Type, 2022–2035

 9.3.3 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Drug / Therapy Class, 2022–2035

 9.3.4 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Route of Administration, 2022–2035

 9.3.5 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By End User, 2022–2035

 9.3.6 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Country, 2022–2035

  9.3.6.1 Germany

  9.3.6.2 UK

  9.3.6.3 France

  9.3.6.4 Italy

  9.3.6.5 Spain

  9.3.6.6 Russia

  9.3.6.7 Poland

  9.3.6.8 Rest of Europe

9.4 Asia-Pacific

 9.4.1 Key Trends

 9.4.2 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Treatment Type, 2022–2035

 9.4.3 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Drug / Therapy Class, 2022–2035

 9.4.4 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Route of Administration, 2022–2035

 9.4.5 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By End User, 2022–2035

 9.4.6 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Country, 2022–2035

  9.4.6.1 China

  9.4.6.2 India

  9.4.6.3 Japan

  9.4.6.4 South Korea

  9.4.6.5 Australia

  9.4.6.6 ASEAN Countries

  9.4.6.7 Rest of Asia-Pacific

9.5 Latin America

 9.5.1 Key Trends

 9.5.2 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Treatment Type, 2022–2035

 9.5.3 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Drug / Therapy Class, 2022–2035

 9.5.4 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Route of Administration, 2022–2035

 9.5.5 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By End User, 2022–2035

 9.5.6 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Country, 2022–2035

  9.5.6.1 Brazil

  9.5.6.2 Argentina

  9.5.6.3 Mexico

  9.5.6.4 Colombia

  9.5.6.5 Rest of Latin America

9.6 Middle East & Africa

 9.6.1 Key Trends

 9.6.2 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Treatment Type, 2022–2035

 9.6.3 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Drug / Therapy Class, 2022–2035

 9.6.4 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Route of Administration, 2022–2035

 9.6.5 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By End User, 2022–2035

 9.6.6 Treatment-Resistant Depression (TRD) Treatment Market Size & Forecast, By Country, 2022–2035

  9.6.6.1 UAE

  9.6.6.2 Saudi Arabia

  9.6.6.3 Qatar

  9.6.6.4 South Africa

  9.6.6.5 Rest of Middle East & Africa

10. Competitive Landscape

 10.1 Key Players' Positioning

 10.2 Competitive Developments

  10.2.1 Key Strategies Adopted (%), By Key Players, 2025

  10.2.2 Year-Wise Strategies & Development, 2022–2025

  10.2.3 Number Of Strategies Adopted By Key Players, 2025

 10.3 Market Share Analysis, 2025

 10.4 Treatment Type/Service & Drug / Therapy Class Benchmarking

  10.4.1 Treatment Type/Service Specifications & Features By Key Players

  10.4.2 Treatment Type/Service Heatmap By Key Players

  10.4.3 Drug / Therapy Class Heatmap By Key Players

 10.5 Industry Start-Up & Innovation Landscape

10.6 Key Company Profiles

 10.6.1 Johnson & Johnson

  10.6.1.1 Company Overview & Snapshot

  10.6.1.2 Treatment Type/Service Portfolio

  10.6.1.3 Key Company Financials

  10.6.1.4 SWOT Analysis

 10.6.2 AbbVie Inc.

     10.6.3 Otsuka Pharmaceutical Co., Ltd.

     10.6.4 Bristol Myers Squibb

     10.6.5 Sage Therapeutics, Inc.

     10.6.6 COMPASS Pathways plc

     10.6.7 MindMed Inc.

     10.6.8 Neuronetics, Inc.

     10.6.9 Magstim

     10.6.10 BrainsWay Ltd.

     10.6.11 Neurocrine Biosciences, Inc.

     10.6.12 Relmada Therapeutics, Inc.

     10.6.13 Alto Neuroscience, Inc.

     10.6.14 Delix Therapeutics

     10.6.15 Beckley Psytech

     10.6.16 GH Research PLC

     10.6.17 ATAI Life Sciences N.V.

     10.6.18 Intra-Cellular Therapies, Inc.

      10.6.19 Acadia Pharmaceuticals Inc.

     10.6.20 Eisai Co., Ltd.

 11. Analyst Recommendations

 11.1 SNS Insider Opportunity Map

 11.2 Industry Low-Hanging Fruit Assessment

 11.3 Market Entry & Growth Strategy

 11.4 Analyst Viewpoint & Suggestions on Market Growth

12. Assumptions

13. Disclaimer

14. Appendix

 14.1 List Of Tables

 14.2 List Of Figures